Research programme: bisphosphocins - Lakewood-Amedex

Drug Profile

Research programme: bisphosphocins - Lakewood-Amedex

Alternative Names: Nu 2; Nu 4; Nu 5; Nu 8; NuBiotics - Lakewood-Amedex; Nubiotics research programme - Oligos Etc.

Latest Information Update: 23 Jan 2017

Price : $50

At a glance

  • Originator Oligos Etc.
  • Developer Lakewood Amedex
  • Class Nucleotides
  • Mechanism of Action Cell membrane structure modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Infections; Urinary tract infections

Most Recent Events

  • 23 Jan 2017 Preclinical trials in Urinary tract infections in USA (IV) before January 207 (Lakewood Amedex pipeline, January 2017)
  • 23 Jan 2017 Lakewood Amedex plans a phase I trial for Urinary tract infections (Lakewood Amedex pipeline, January 2017)
  • 29 Apr 2016 Preclinical trials in Infections in USA (unspecified route) prior to April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top